Premier Alternatives

Peptilogics

Pittsburgh, PA · Founded 2013 · Privately Held (backing)

Developer of a therapeutic and drug discovery peptide platform designed to treat multidrug-resistant bacterial infections. Peptilogics is based in Pittsburgh, PA and was founded in 2013. It was valued at $150 million at its later-stage round in May 2025, the last priced event on record. It has raised $195 million across 4 recorded rounds; the latest was a $35.8 million early-stage round in Dec 2020.

PMV mark · valuation
$150.0M
Oct 2026
Priced at
its later-stage round
May 2025
Total raised
$194.8M
Last round
Early Stage VC
Dec 2020

Peptilogics key facts

as of Oct 2026
  • Developer of a therapeutic and drug discovery peptide platform designed to treat multidrug-resistant bacterial infections.
  • Peptilogics is valued at approximately $150.0M as of Oct 2026, set at its later-stage round, May 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $194.8M across 4 recorded rounds; the latest was Early Stage VC ($35.8M) in Dec 2020.
  • Notable investors include Gaingels, Founders Fund, Innovation Works, Alpha Wave Global, Peter Thiel — 30 tracked in total.
  • Peptilogics has filed 4 Form Ds with the SEC since 2016, most recently Dec 2020 ($35.8M sold to 19 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$150.0M

Valued at $150.0M at its later-stage round, May 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Peptilogics with a free account
  • ·The complete investor list: 30 names
  • ·Watch Peptilogics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Peptilogics funding rounds

4 rounds
Dec 2020Early Stage VC$35.8MSEC filing▮
Aug 2017Seed Round$4.0MSEC filing▮
May 2017Seed Round$754KSEC filing▮
Jan 2016Seed Round$417KSEC filing▮
Full funding history →

Peptilogics valuation

Peptilogics was valued at $150 million at its later-stage round in May 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Peptilogics raised?

Peptilogics has raised $195 million in total; 4 of its rounds are on record, from 2016 on. The largest on record was a $753,999 seed round in May 2017; the most recent was a $35.8 million early-stage round in Dec 2020.

Peptilogics has filed 4 Form Ds with the SEC since 2016, most recently in Dec 2020 ($35.8 million sold to 19 investors).

Peptilogics investors

30 investors are on record for Peptilogics, including Gaingels, Founders Fund, Innovation Works and Alpha Wave Global. By type, the record holds 3 venture capital firms and 2 family offices. The early-stage round in Dec 2020 drew 19 investors.

About Peptilogics

Developer of a therapeutic and drug discovery peptide platform designed to treat multidrug-resistant bacterial infections. The company's platform offers a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) that has preclinical effectiveness against resistant bacteria and biofilms, enabling doctors to identify and treat bacterial infections at an affordable cost.

Sector
Healthcare
HQ
Pittsburgh, PA, United States
Founded
2013
Employees
21
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.